JPX · 4588.T
Oncolys BioPharma Inc.
¥7,560+¥160 (+2.16%)
Oncolys BioPharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.5% below the high.
Loading market information…
JPX · 4978.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
ReproCELL Incorporated’s quoted price sits in the lower half of its reported 52-week range, 40.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ReproCELL Incorporated’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ReproCELL Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:01 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Nov 13, 2024 |
| -¥0+75.0% vs estimate |
| ¥701M+25.18% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥7,560+¥160 (+2.16%)
Oncolys BioPharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.5% below the high.
¥1,684¥0 (0.0%)
Medical Data Vision Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
¥1,633¥0 (0.0%)
CE Holdings Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 12.16% below the high.
¥629-¥138 (-17.99%)
Japan Tissue Engineering Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.15% below the high.
¥785-¥1 (-0.13%)
SEED Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 1.13% below the high.
¥638-¥9 (-1.39%)
RaQualia Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.45% below the high.
¥749-¥17 (-2.22%)
CanBas Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 24.42% below the high.
¥1,150-¥2 (-0.17%)
Wellness Communications Corporation’s quoted price sits in the lower half of its reported 52-week range, 24.34% below the high.
